A Dual-Antigen Enzyme-Linked Immunosorbent Assay Allows the Assessment of Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Seroprevalence in a Low-Transmission Setting. (3rd October 2020)

• Record Type: Journal Article
• Authors: Hicks, Sarah M; Pohl, Kai; Neeman, Teresa; McNamara, Hayley A; Parsons, Kate M; He, Jin-shu; Ali, Sidra A; Nazir, Samina; Rowntree, Louise C; Nguyen, Thi H O; Kedzierska, Katherine; Doolan, Denise L; Vinuesa, Carola G; Cook, Matthew C; Coatsworth, Nicholas; Myles, Paul S; Kurth, Florian; Sander, Leif E; Mann, Graham J; Gruen, Russell L; George, Amee J; Gardiner, Elizabeth E; Cockburn, Ian A
• Is Part Of: Journal of infectious diseases. Volume 223:Number 1(2021)
• Page Start: 10
• Page End: 14
• Publication Date: 2020-10-03
• Subjects: SARS-CoV-2 -- COVID-19 -- seroprevalence -- ELISA -- antibodies; Communicable diseases -- Periodicals; Diseases -- Causes and theories of causation -- Periodicals; Medicine -- Periodicals; Communicable Diseases -- Periodicals; Electronic journals; 616.9
• DOI: 10.1093/infdis/jiaa623
• Languages: English
• ISSNs: 0022-1899

Abstract

Abstract: Estimates of seroprevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies have been hampered by inadequate assay sensitivity and specificity. Using an enzyme-linked immunosorbent assay–based approach that combines data about immunoglobulin G responses to both the nucleocapsid and spike receptor binding domain antigens, we show that excellent sensitivity and specificity can be achieved. We used this assay to assess the frequency of virus-specific antibodies in a cohort of elective surgery patients in Australia and estimated seroprevalence in Australia to be 0.28% (95% Confidence Interval, 0–1.15%). These data confirm the low level of transmission of SARS-CoV-2 in Australia before July 2020 and validate the specificity of our assay. Abstract : The determination of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody seroprevalence in low-transmission settings requires highly sensitive and specific assays. We combined data about antibody responses to the spike receptor binding domain and nucleocapsid to confirm the low prevalence of SARS-CoV-2 in Australia.